Biomea Fusion Inc. reported its third quarter 2025 financial results and provided a corporate update. The company advanced its diabetes and obesity programs, noting that icovamenib, its oral small molecule menin inhibitor, demonstrated durable 52-week Phase II data with continued reduction in HbA1c nine months after dosing in identified target populations and maintained a safety profile comparable to placebo. Biomea Fusion also dosed its first patient in a Phase I clinical trial of BMF-650, an oral GLP-1 receptor agonist. Preclinical data presented at the EASD Annual Meeting showed that icovamenib combined with semaglutide in a type 2 diabetes animal model resulted in enhanced glycemic control and body weight reduction with preservation of lean mass. The company streamlined operations during the quarter, reducing its workforce to approximately 40 employees and achieving a year-over-year decrease of more than 50% in operating expenses. Biomea Fusion raised approximately $68 million in gross proceeds through two public offerings, extending its projected cash runway into the first quarter of 2027. The company also completed a $25 million underwritten public offering in October 2025. The ongoing Food Effect Study (COVALENT-121) for icovamenib is expected to be completed by December 2025.